Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 3/20 | 0.49 |
| ▸ | MAOB | P27338 | 3/20 | 0.49 |
| ▸ | SLC6A19 | Q695T7 | 1/20 | 0.49 |
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.45 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | PAM | P19021 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21791369 | 1.00 | HSD17B3 (0.56) | HSD17B3MAOAMAOBSLC6A19BACE1 | |
| SCHEMBL571592 | 1.00 | HSD17B3 (0.56) | HSD17B3MAOAMAOBSLC6A19BACE1 | |
| SCHEMBL9232628 | 0.91 | HSD17B3 (0.53) | HSD17B3MAOAMAOBSLC6A19BACE1 | |
| SCHEMBL9232633 | 0.91 | HSD17B3 (0.53) | HSD17B3MAOAMAOBSLC6A19BACE1 | |
| SCHEMBL7612524 | 0.83 | PAM (0.65) | HSD17B3MAOAMAOBSLC6A19BACE1 | |
| SCHEMBL7612527 | 0.83 | PAM (0.65) | HSD17B3MAOAMAOBSLC6A19BACE1 | |
| SCHEMBL21901276 | 0.82 | SLC6A19 (0.51) | HSD17B3MAOAMAOBSLC6A19BACE1 | |
| SCHEMBL666894 | 0.81 | PAM (0.64) | MAOBALDH1A1CYP2D6TBXAS1MAPT | |
| SCHEMBL1232837 | 0.81 | PAM (0.64) | MAOBALDH1A1CYP2D6TBXAS1MAPT | |
| SCHEMBL1231739 | 0.81 | PAM (0.64) | MAOBALDH1A1CYP2D6TBXAS1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415803-B2 | Fused imidazopyridines as reversible inhibitors of Brutons Tyrosine Kinase (BTK) | MERCK PATENT GMBH (DE) | 2025-09-16 | — | — | US | disclosed |
| CN-117567453-A | Benzazepine analogs as inhibitors of bruton's tyrosine kinase | 渤健马萨诸塞州股份有限公司 | 2024-02-20 | — | — | CN | disclosed |
| EP-3609886-B1 | BENZOAZEPINE ANALOGS AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC (US) | 2024-02-07 | — | — | EP | disclosed |
| US-11858926-B2 | Inhibiting agents for bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858926-B2 | Inhibiting agents for bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858926-B2 | Inhibiting agents for bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2024-01-02 | — | — | US | disclosed |
| EP-4249071-A2 | BENZOAZEPINE ANALOGS AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | Biogen MA Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-4249071-A2 | BENZOAZEPINE ANALOGS AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | Biogen MA Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| CN-110621670-B | Benzazepine analogs as inhibitors of bruton's tyrosine kinase | 比奥根MA公司 | 2023-09-15 | — | — | CN | disclosed |
| EP-3444251-B1 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | BIOGEN MA INC (US) | 2023-06-07 | — | — | EP | disclosed |
| WO-2010096302-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-26 | — | — | WO | disclosed |
| US-20100215616-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-26 | — | — | US | disclosed |
| WO-2010096302-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-26 | — | — | WO | disclosed |
| US-20100215616-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-26 | — | — | US | disclosed |
| US-20100215616-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-26 | — | — | US | disclosed |
| WO-2009102633-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-20 | — | — | WO | disclosed |
| WO-2009102633-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-20 | — | — | WO | disclosed |
| US-20090202478-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-08-13 | — | — | US | disclosed |
| US-20090202478-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-08-13 | — | — | US | disclosed |
| US-20090202478-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100215616-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | HSD17B3 1752/4885MAOA 2242/4885MAOB 1297/4885 |
| US-20090202478-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | HSD17B3 1752/4885MAOA 2242/4885MAOB 1297/4885 |
| US-12415803-B2 | Fused imidazopyridines as reversible inhibitors of Brutons Tyrosine Kinase (BTK) | BTK, SYK, ABL1 | HSD17B3 4221/4885MAOA 3594/4885MAOB 2832/4885 |
| US-11858926-B2 | Inhibiting agents for bruton's tyrosine kinase | ABL1, BTK, LYN | HSD17B3 2992/4885MAOA 2068/4885MAOB 1204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.